Acute myeloid leukemia, characterized by the rapid proliferation of dysfunctional myeloid cells in the bone marrow, often develops resistance to conventional chemotherapy regimens. This resistance stymies treatment efficacy, leading to poor prognoses and limited long-term survival. The study, conducted by Zhao et al., delves into the molecular underpinnings that allow AML cells to endure chemotherapeutic assaults, positioning oxidative stress regulation via the Nrf2/ARE pathway as a key player in mediating this resistance.

Venetoclax, an FDA-approved agent, targets the anti-apoptotic protein BCL-2, thereby promoting programmed cell death in leukemia cells. Despite its initial efficacy, resistance emerges, diminishing its therapeutic benefit. Addressing this challenge, the research introduces ML385, a selective inhibitor of Nrf2 that suppresses antioxidant response element (ARE)-driven gene expression, effectively dismantling the AML cells’ defense mechanisms against oxidative damage.

Oxidative stress has long been recognized as a double-edged sword in cancer biology. While excessive reactive oxygen species (ROS) can induce cytotoxicity and apoptosis, cancer cells often exploit antioxidant pathways, mediated by Nrf2, to mitigate ROS and survive under oxidative duress. By inhibiting Nrf2, ML385 compromises AML cells’ antioxidant defenses, rendering them vulnerable to oxidative stress and apoptosis, particularly when combined with Venetoclax’s pro-apoptotic effects.

The comprehensive investigation revealed that the combination therapy significantly reduced viability of AML cells that were previously resistant to chemotherapy. This effect is attributable to the downregulation of Nrf2 and its downstream targets, leading to an accumulation of intracellular ROS. This oxidative overload tips the balance towards cell death, a strategy that could potentially be generalized to other malignancies exhibiting similar resistance mechanisms.

Beyond cellular assays, the research incorporated in vivo models that corroborated the enhanced antileukemic activity of Venetoclax and ML385 co-administration. Treated subjects exhibited marked reductions in leukemic burden and improved survival outcomes without notable increases in toxicity, underscoring the therapeutic promise and tolerability of this approach.

One intriguing facet of this study lies in its elucidation of the molecular crosstalk between apoptotic pathways and oxidative stress regulation. The data suggest that targeting Nrf2 not only sensitizes AML cells to oxidative damage but may also enhance the intrinsic apoptotic pathways modulated by Venetoclax, creating a multi-pronged attack on leukemia cells.

The implications of this research extend far beyond the immediate clinical application for AML. Given the central role of oxidative stress and Nrf2 in a myriad of cancers and chemoresistance phenotypes, ML385 or similar agents could redefine resistance management and improve outcomes in diverse oncological contexts.

Importantly, this study opens discourse on the customization of cancer therapies based on molecular vulnerabilities, advocating for integrative treatment modalities that combine direct cell death induction with metabolic and oxidative modulation.

While these findings are promising, the transition from bench to bedside necessitates rigorous clinical trials to evaluate efficacy, safety, dosing strategies, and potential resistance mechanisms that could emerge with combined Venetoclax and ML385 treatment.

Moreover, the study prompts further exploration into biomarkers predictive of Nrf2 pathway activation in AML patients, enabling precision medicine approaches tailored to individual tumor biology and resistance profiles.

The utilization of ML385 also invites consideration of its pharmacodynamic and pharmacokinetic properties, potential off-target effects, and compatibility with existing chemotherapeutics to optimize its integration into standard care protocols.

This research represents a vital stride in overcoming the persistent challenge of chemotherapy resistance in AML, showcasing the power of targeted pathway inhibition combined with apoptotic induction to dismantle cancer cell defenses.

In conclusion, the study by Zhao et al. offers a compelling paradigm shift in AML treatment strategies by leveraging the vulnerabilities associated with oxidative stress regulation. By combining Venetoclax with ML385, there is renewed hope for overcoming resistance and achieving more durable remissions in this aggressive hematological malignancy.

As the oncology community continues to unravel the intricate molecular pathways involved in cancer persistence and resistance, these findings herald a new era of combination therapies designed not just to kill cancer cells, but to dismantle their survival networks from multiple angles simultaneously.

This innovative approach is not only scientifically elegant but also clinically imperative, promising to enhance the effectiveness of existing drugs and ultimately improve patient outcomes in a disease area with significant unmet needs.

Subject of Research: Therapeutic strategy combining Venetoclax with ML385 to overcome chemotherapy resistance in acute myeloid leukemia via modulation of Nrf2/ARE-mediated oxidative stress.

Article Title: Venetoclax combined with ML385 overcomes chemotherapy resistance in acute myeloid leukemia by modulating Nrf2/ARE-mediated oxidative stress.

Article References:
Zhao, L., Guo, Y., Jian, J. et al. Venetoclax combined with ML385 overcomes chemotherapy resistance in acute myeloid leukemia by modulating Nrf2/ARE-mediated oxidative stress. Med Oncol 43, 114 (2026). https://doi.org/10.1007/s12032-025-03229-8

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-025-03229-8

Central among these discoveries is the revelation that intestinal metabolism critically governs the regeneration and differentiation of intestinal stem cells, a process vital for maintaining gut integrity. The intestinal lining is one of the most rapidly renewing tissues in mammals, with stem cells continuously differentiating to replenish diverse cell types needed for nutrient absorption and microbial defense. MSK researchers used sophisticated genetically engineered mouse models and three-dimensional organoid cultures to dissect how specific metabolites influence the fate decisions of these stem cells within living organisms. Their work highlights alpha-ketoglutarate, a key metabolite traditionally recognized for its role in cellular energy cycles, as a pivotal signaling molecule orchestrating stem cell differentiation toward protective intestinal cell lineages.

This nuanced function of alpha-ketoglutarate reshapes our understanding of metabolic regulation in tissue regeneration. Beyond merely fueling bioenergetic demands, such metabolites appear to act as molecular directors, actively shaping cell identity and tissue architecture during regeneration. In mouse models mimicking ulcerative colitis, a chronic inflammatory disease that compromises intestinal barrier function, supplementation with alpha-ketoglutarate restored deficient differentiation pathways and accelerated mucosal healing. This finding carries substantial weight, as chronic inflammation is a recognized precursor to colorectal cancer. Thus, modulating metabolic pathways to enhance stem cell-driven tissue repair not only offers therapeutic avenues for inflammatory bowel diseases but also for cancer prevention.

Previous investigations by the same lab have implicated alpha-ketoglutarate in enhancing the tumor-suppressive function of p53, the “guardian of the genome.” Given that p53 dysfunction is common in pancreatic and other cancers, boosting alpha-ketoglutarate levels may offer a metabolic approach to reinstate tumor suppression. Taken together, these insights reveal a dual role for metabolites in both maintaining tissue homeostasis and restraining oncogenesis, forging new paths in regenerative medicine and metabolic oncology.

Shifting focus to breast cancer, MSK scientists have uncovered a molecular mechanism driving resistance to hormonal and targeted therapies, mediated by the APOBEC3 family of enzymes. While APOBEC3 proteins are chiefly recognized for their antiviral defenses—inducing mutations to disrupt viral genomes—emerging evidence implicates their mutagenic activity in cancer evolution. Analyzing nearly four thousand patient tumor samples, the research team identified distinct mutational signatures attributable to APOBEC3 enzymes. Crucially, these mutational patterns correlated with shortened progression-free survival among patients undergoing endocrine and targeted treatments, highlighting APOBEC3 activity as a biomarker and contributor to therapeutic failure.

One pivotal mutation linked to APOBEC3-mediated mutagenesis is the loss of RB1, a tumor suppressor gene integral to cell cycle regulation. The accumulation of these mutations fosters genomic instability, enabling cancer cells to evade growth controls and resist therapy. Notably, the presence of APOBEC3-induced changes in pre-treatment tumors underscores their role not only in resistance development but also in the initiation and progression of malignancy. These findings elevate APOBEC3 enzymes as promising targets for therapeutic intervention, potentially disrupting the mutational processes that fuel breast cancer resilience.

In a complementary study probing resistance mechanisms in estrogen receptor-positive (ER+) breast cancer, researchers employed CRISPR-Cas9 genetic screening to spotlight NR2F2, a transcription factor implicated in suppressing estrogen receptor signaling. Endocrine therapies, fundamental to managing ER+ breast cancer, function by blocking estrogen-driven proliferation. However, resistance frequently arises, undermining treatment efficacy. The discovery that NR2F2 modulates gene networks to dampen ER signaling clarifies one pathway through which tumors circumvent hormonal intervention.

Functional assays using patient-derived tumor models demonstrated that pharmacological inhibition or genetic ablation of NR2F2 restored sensitivity to endocrine therapies. This breakthrough paves the way for novel therapeutic combinations that could resensitize resistant tumors by targeting NR2F2-mediated transcriptional repression. Such precision medicine strategies promise to extend the durability of current hormonal treatments and improve patient survival.

Beyond molecular and cellular investigations, MSK’s clinical research has explored integrative therapies to alleviate treatment-related side effects in cancer survivors. A randomized pilot trial evaluated acupuncture’s efficacy in mitigating nocturia—a distressing condition characterized by frequent nighttime urination, which is highly prevalent among men treated for prostate cancer. This condition disrupts sleep and erodes quality of life, often persisting years after cancer treatment completion. The trial enrolled 60 men with a history of varied prostate cancer therapies, including surgery, radiation modalities, and hormone therapy.

Participants randomized to a regimen of weekly acupuncture sessions for ten weeks exhibited a significant reduction in nocturnal urination frequency compared to controls receiving standard care. On average, acupuncture recipients woke up approximately one less time per night, with benefits sustained beyond the intervention period. Importantly, no serious adverse events were associated with the acupuncture treatments. This pilot study offers encouraging evidence supporting acupuncture as a safe, non-pharmacological option to improve urinary symptoms and sleep quality in prostate cancer survivors, meriting further investigation in larger, controlled trials.

Taken together, these multifaceted research advances from MSK embody a holistic approach to cancer science, integrating molecular biology, genetic engineering, metabolic biochemistry, and patient-centered clinical research. They unravel fundamental disease mechanisms while simultaneously advancing tangible therapeutic solutions—from metabolite-based tissue regeneration strategies and targeted inhibition of resistance drivers to integrative therapies enhancing survivorship. As these insights translate into clinical innovations, they hold promise to redefine standards of care across oncology disciplines.

Future research will undoubtedly delve deeper into the mechanistic intricacies unveiled by these studies, elucidating how metabolic cues intersect with genetic pathways to govern cancer initiation, progression, and response to treatment. Furthermore, translating findings regarding APOBEC3 and NR2F2 into targeted drug development could transform therapeutic landscapes, offering new hope for overcoming resistance in aggressive breast cancers. Meanwhile, integrating complementary modalities such as acupuncture into survivorship care exemplifies a patient-centered paradigm addressing the broad spectrum of symptoms experienced by cancer patients beyond tumor control.

Memorial Sloan Kettering’s continued commitment to pioneering interdisciplinary cancer research positions the field toward a future where precision-targeted metabolic modulation, genomic stability preservation, and holistic symptom management converge to optimize outcomes for millions affected by cancer worldwide.

Subject of Research: Cancer Biology and Therapeutics, Metabolic Regulation, Breast and Prostate Cancer Resistance, Integrative Oncology

Article Title: Metabolic Insight Reveals New Frontiers in Cancer Regeneration and Resistance

News Publication Date: 2024

Web References:

• https://www.nature.com/articles/s41586-025-09097-6
• https://www.nature.com/articles/s41588-025-02187-1
• https://www.science.org/doi/10.1126/scitranslmed.adk7786
• https://jamanetwork.com/journals/jamaoncology/article-abstract/2834640

References:

• Chaves-Perez, A., Millman, S., & Lowe, S.W. et al. (2024).
• Chandarlapaty, S. et al. (2024).

Image Credits: Memorial Sloan Kettering Cancer Center

Keywords: Cancer research, Basic research, Prostate cancer, Breast cancer